Efficacy of N-acetyl-cysteine in combination with thiamphenicol in sequential (intramuscular/aerosol) therapy of upper respiratory tract infections even when sustained by bacterial biofilms

Journal of Chemotherapy

Volumn 18, Issue 5, 2006, Pages 507-513

  Macchi, A ^a   Ardito, F ^b   Marchese, Anna ^c   Schito, G C ^c   Fadda, G ^b  

^a OSPEDALE DI CIRCOLO   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Recurrent upper respiratory infections; Respiratory pathogens; Thiamphenicol glycinate acetylcysteinate

Indexed keywords

ACETYLCYSTEINE; THIAMPHENICOL;

ABSENCE OF SIDE EFFECTS; ADULT; AEROSOL; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BIOFILM; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; RHINOSINUSITIS; SCANNING ELECTRON MICROSCOPY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TONSILLITIS; TREATMENT FAILURE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

EID: 33751197878     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.5.507     Document Type: Article

References (38)

1. Shah PM. Sequential or switch treatment - which criteria should be fulfilled? Int J Antimicrob Agents 2000; 16 (3): 301-302.
2. Lelekit M, Gould M. Sequential antibiotic therapy for cost containment in the hospital setting: why not? J Hosp Infect 2001; 48: 249-257.
3. Davis SL, Delgado G Jr, McKinnon PS. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis 2005; 41 (Suppl 2): S136-S143.
4. Pablos AI, Escobar I, Albinana S, Serrano O, Ferrari JM, Herreros de Tejada A. Evaluation of an antibiotic intravenous to oral sequential therapy program. Pharmacoepidemiol Drug Saf 2005; 14 (1): 53-59.
5. Farley A, Hendry C, Napier P. Paracetamol poisoning: physiological aspects and management strategies. Nurs Stand 2005; 19 (38): 58-64.
6. Peake J, Sukuki K. Neutrophil activation, antioxidant supplements and exercise-induced oxidative stress. Exerc Immunol Rev 2004; 10: 129-41.
7. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr 2004; 134 (3): 489-492.
8. Yuta A, Baraniuk JN. Therapeutic approaches to mucus hypersecretion. Curr Allergy Asthma Rep 2005; 5 (3): 243-251.
9. Guerin JC, Leophonte P, Lebas FX, Liard F, Terrioux P, Boulanger P. Oxidative stress in bronchopulmonary disease: contribution of N-acetylcysteine (NAC). Rev Pneumol Clin 2005; 61 (1): 16-21.
10. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23 (4): 629-636.
11. Marchese A, Debbia EA, Tonoli E, Gualco L, Schito AM. In vitro activity of thiamphenicol against multiresistant Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in Italy. J Chemother 2002; 14 (6): 554-561.
12. Raymond J, Boutros N, Bergeret M. Role of thiamphenicol in the treatment of community-acquired lung infections. Med Trop 2004; 64 (1): 33-38.
13. Ferrari V. Salient features of thiamphenicol: review of clinical pharmacokinetics and toxicity. Sex Trasm Dis 1984; 11 (Suppl 4): S336-S339.
14. Grassi C, Benedetto F. Recent clinical evidence of the efficacy and safety of thiamphenicol glycinate acetylcysteinate and thiamphenicol glycinate. J Chemother 2002; 14 (3): 279-284.
15. Turton JA, Havard AC, Robinson S, et al. An assessment of chloramphenicol and thiamphenicol in the induction of aplastic anaemia in the BALB/c mouse. Food Chem Toxicol 2000; 38 (10): 925-938.
16. Kobayashi H. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections. Treat Respir Med 2005;4 (4): 241-253.
17. Schwarz S, Kehrenberg C, Doublet B, Cloeckaert A. Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol Rev 2004; 28 (5): 519-542.
18. Kierek-Pearson K, Karatan E. Biofilm development in bacteria. Adv Appl Microbiol 2005; 57: 79-111.
19. Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol 2005; 13 (1): 34-40.
20. Fux CA, Costerton JW, Stewart PS, Stoodley P. The role of biofilms in otolaryngologic infections. Curr Opin Otolaryngol Head Neck Surg 2004; 12 (3): 185-190.
21. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest 2003; 112 (10): 1466-1477.
22. Perez-Giraldo C, Rodriguez Benito A, Moran FJ, Hurtado C, Blanco MT, Gomez-Garcia AC. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J Ant Chem 1997; 39 (5): 643-646.
23. Olofsson AC, Hermansson M, Elwing H. N-acetyl-t-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces. Appl Environ Microbiol 2003; 69 (8): 4814-4822.
24. Bozzolasco M, Debbia EA, Schito AM. Rilevanza dei biofilm batterici nelle infezioni respiratorie: problematiche terapeutiche e possibili soluzioni. Giorn Ital Microbiol Med Odontoiatr 2002; 6 (3): 203-215.
25. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 15th International Supplement. CLSI document M100-S15. Wayne, PA: CLSI; 2005.
26. Albini E, Belluco G, Berton G, Schiappacassi M, Ungheri D. In vitro antibacterial activity of thiamphenicol glycinate acetyl cysteinate against respiratory pathogens. Drug Res 1999; 49 (6):533-537.
27. Cramton SE, Gerke C, Gotz F. In vitro methods to study biofilm formation. Methods Enzymol 2001; 336: 239-255.
28. Marchese A, Bozzolasco M, Gualco L, Debbia EA, Schito GC, Schito AM. Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. Int J Antimicrob Agents 2003; 22 (Suppl 2): S95-S100.
29. Brook I. Anaerobic bacteria in upper respiratory tract and other head and neck infections. Ann Otol Rhinol Laryngol 2002; 111 (5): 430-40.
30. Araujo E, Palombini BC, Cantarelli V, Pereira A, Mariante A. Microbiology of middle meatus in chronic rhinosinusitis. Am J Rhinol 2003; 17 (1): 9-15.
31. Schito GC. Resistance trends in Streptococcus pneumonias (PROJEKT years 1-3 [1999-2002]). J Chemother 2004; 16 (Suppl 6): S19-S33.
32. Schito GC, Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROJEKT 1999-2003). Int J Antimicrob Agents 2005; 26 (6): 479-485.
33. Marchese A, Gualco L, Cochetti I, et al. Antibiotic susceptibility and serotype distribution in Streptococcus pneumoniae circulating in Italy: results of the SEMPRE surveillance study (2000-2002). Int J Antimicrob Agents 2005; 26 (2): 138-145.
34. Marchese A, Fontana R, Lo Cascio G, Nicoletti G, Speciale AM, Schito GC. The Sentinel Project: an update on the prevalence of antimicrobial resistance in community-acquired respiratory Streptococcus pneumoniae and Haemophilus spp. in Italy. Int J Antimicrob Agents 2005; 26 (1): 8-12.
35. Donlan RM, Piede JA, Heyes CD, et al. Model system for growing and quantifying Streptococcus pneumoniae biofilms in situ and in real time. Appl Environ Microbiol 2004; 70 (8): 4980-8.
36. Sanclement JA, Webster P, Thomas J, Ramadan HH. Bacterial biofilms in surgical specimens of patients with chronic rhinosinusitis. Laryngoscope 2005; 115 (4): 578-582.
37. Chole RA, Faddis BT. Anatomical evidence of microbial biofilms in tonsillar tissues: a possible mechanism to explain chronicity. Arch Otolaryngol Head Neck Surg 2003; 129 (6): 634-636.
38. Ramadan HH, Sanclement JA, Thomas JG. Chronic rhinosinusitis and biofilms. Otolaryngol Head Neck Surg 2005; 132: 414-417.